Skip to main content

Pharma

By Dave Muoio | 02:28 pm | April 19, 2018
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
By MobiHealthNews | 04:47 pm | April 13, 2018
Pharma companies have been eying digital health with interest, and the first quarter of 2018 was no exception.
By Dave Muoio | 11:04 am | April 12, 2018
ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph.
By Susan Morse | 05:30 pm | April 04, 2018
Five healthcare organizations including insurers UnitedHealthcare and Humana, Optum, Quest Diagnostics, and MultiPlan are launching a blockchain pilot to help payers tackle mandated provider directories.
By Dave Muoio | 05:25 pm | April 04, 2018
Pfizer announced today that it is receiving applications for its Pfizer Healthcare Hub: London competitive grant.
By Jonah Comstock | 03:59 pm | April 03, 2018
Walmart is reportedly in talks to acquire PillPack, a New England-based virtual pharmacy with around $100 million in funding.
By Jonah Comstock | 03:34 pm | March 16, 2018
Platinum Equity, a Los Angeles-based global investment firm focused on mergers, acquisitions, and operations, has made a binding offer to acquire Johnson & Johnsons' Chesterbrook, Pennsylvania and Zug, Switzerland-based LifeScan business, which sells the OneTouch line of connected and non-connected glucometers.
By Jonah Comstock | 05:56 pm | March 12, 2018
Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18.
By Laura Lovett | 12:46 pm | March 02, 2018
Artificial intelligence has been working its way into the field of research.
By Jonah Comstock | 04:36 pm | March 01, 2018
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia.